Table 1.
Baseline characteristics.
| Rivoceranib N = 80 | |
|---|---|
| Median age, y (range) | 54.5 (28–76) |
| Male, n (%) | 42 (52.5) |
| Female, n (%) | 38 (47.5) |
| Race or ethnicity, n (%) | |
| White | 47 (58.8) |
| Asian | 28 (35.0) |
| Black or African American | 2 (2.5) |
| Other race | 3 (3.8) |
| Hispanic or Latino | 7 (8.8) |
| ECOG PS, n (%) | |
| 0 | 45 (56.2) |
| 1 | 35 (43.8) |
| Primary tumor location, n (%) | |
| Major salivary gland | 27 (33.8) |
| Minor salivary gland | 47 (58.8) |
| Othera | 6 (7.5) |
| Stageb at study entry, n (%) | |
| II | 1 (1.3) |
| IVA | 2 (2.5) |
| IVB | 3 (3.8) |
| IVC | 74 (92.5) |
| Sites of metastases,cn (%) | |
| Lung | 69 (86.3) |
| Liver | 25 (31.3) |
| Lymph nodes (distant) | 20 (25.0) |
| Bone | 20 (25.0) |
| Pleura | 14 (17.5) |
| Peritoneum | 7 (8.8) |
| Kidney | 6 (7.5) |
| Brain | 4 (5.0) |
| Soft tissue | 3 (3.8) |
| Other | 9 (11.3) |
| Genetic alterations, n/N (%)d | |
| MYB-NFIB gene fusion | 23/62 (37.1) |
| MYBL1-NFIB gene fusion | 6/62 (9.7) |
| NOTCH1 mutation | 2/27 (7.4) |
| Prior local treatments, n (%) | |
| Surgery | 71 (88.8) |
| Radiotherapy | 77 (96.3) |
| Prior systemic therapy,en (%) | 49 (61.3) |
| Median number of lines (range) | 1.0 (0, 8) |
| ≥3 lines | 16 (20.0) |
| Prior VEGFR inhibitorf | 14 (17.5) |
| Lenvatinib | 10 (12.5) |
| Axitinib | 4 (5.0) |
| Prior chemotherapy | 37 (46.3) |
aLung (n = 2); breast, trachea, Cowper's gland, and intracranial tumor (right temporal region; n = 1 each).
bStaging was per the American Joint Committee on Cancer.
cTotal is greater than 100% as the categories are not mutually exclusive.
dBased on archival tumor samples.
eExcludes chemotherapy given in the adjuvant, neoadjuvant, or maintenance settings.
fNo patients received >1 line of prior VEGFRi therapy.